Dr. Reddy`s Laboratories Total Revenue

The latest total revenue for RDY is $330B as of June 2026. That compares with $330B in the prior-year period — down 0.4% year over year. That is above the Healthcare sector average of $110B. Investors often review this figure alongside Dr. Reddy`s Laboratories's historical trend and sector peers before judging valuation or financial health.

Over the past year, RDY's total revenue moved from $330B to $330B — a 0.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Dr. Reddy`s Laboratories's operating scale or balance-sheet position.

Against Healthcare companies, RDY currently prints $330B for total revenue, while the sector average sits near $110B. That is roughly 193.6% above the sector mean. Large gaps often invite a closer look at Dr. Reddy`s Laboratories's growth, margins, and balance sheet.

A total revenue figure of $330B for RDY is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting RDY's total revenue ($330B), review year-over-year change from $330B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.